After months of deliberation, the Colombian government has issued a compulsory license for an HIV medicine, the first time the country has taken such a step, one that also marks a significant move in the increasingly global battle over access to medicines.
The license is designed so that tens of thousands of Colombians can obtain a lower-cost version of dolutegravir, a medicine that is manufactured and sold by ViiV Healthcare, a company that specializes in HIV treatments and is largely controlled by GSK. Dolutegravir is recommended by the World Health Organization as part of the preferred first-line treatment regimen for people living with HIV.
A compulsory license allows a country to grant a license to a public agency or a generic drugmaker to copy a patented medicine without the consent of the brand-name company that owns the patent. The right to take this step, which can be used to lower the cost of a prescription medicine, was memorialized in a World Trade Organization agreement. (Here is a primer.)
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.